PDE4B Inhibitor Market Summary
The Phosphodiesterase 4B (PDE4B) inhibitor market in the 7MM is projected to grow at a significant CAGR by 2034 across the leading countries (US, EU4, UK, and Japan). PDE4B inhibitors represent a promising class of targeted therapies with the potential to reshape treatment paradigms across pulmonary, inflammatory, and neuropsychiatric diseases, with their isoform selectivity offering a clinical edge by balancing efficacy with improved tolerability. Currently approved PDE4 inhibitors such as OHTUVAYRE (ensifentrine), ZORYVE (roflumilast), and EUCRISA (crisaborole) validate the therapeutic relevance of PDE4 modulation, while emerging candidates like tanimilast (CHF6001) and ALTO-101 reflect sustained pipeline interest in more selective, better-tolerated therapies. Merck’s $10 billion acquisition of Verona Pharma, announced in July 2025, further underscores industry confidence in the PDE4 therapeutic class.
Explore DelveInsight’s Full Coverage on the PDE4B Inhibitor Market
PDE4B Inhibitor Overview
A PDE4B inhibitor is a small molecule that selectively inhibits PDE4B, an enzyme primarily responsible for degrading cyclic adenosine monophosphate (cAMP) within immune and inflammatory cells. By blocking PDE4B, these inhibitors elevate intracellular cAMP levels, leading to anti-inflammatory and antifibrotic effects. PDE4B inhibitors are under development and clinical investigation for a range of therapeutic applications, including pulmonary fibrosis, chronic inflammatory diseases, schizophrenia, and related disorders. Their selectivity for PDE4B over other isoforms like PDE4D aims to achieve efficacy while minimizing side effects such as nausea, which are commonly associated with broad-spectrum PDE4 inhibition.
PDE4B Inhibitor Clinical Relevance
PDE4B inhibitors are emerging as a versatile class with strong potential across respiratory, dermatology, and neuropsychiatry. In respiratory care, their application in COPD, NCFB, cystic fibrosis, and asthma offers opportunities to address persistent inflammation and gaps in disease control. In dermatology, indications such as plaque psoriasis, atopic dermatitis, and seborrheic dermatitis represent commercially attractive markets supported by the established efficacy of PDE4 inhibition in skin inflammation. Expanding into CIAS (Cognitive Impairment Associated with Schizophrenia) further broadens their scope, opening a differentiated growth avenue for the class.
Factors Driving the PDE4B Inhibitor Market Growth
- High chronic disease burden: Persistently increasing global prevalence of chronic inflammatory conditions including COPD, asthma, psoriasis, atopic dermatitis, inflammatory bowel disease, and psoriatic arthritis is creating an expanding patient base
- Physician and patient preference shift: Growing preference for non-steroidal, targeted anti-inflammatory options for long-term disease control, avoiding corticosteroid side effects
- Pipeline advancement: Emerging candidates including tanimilast (CHF6001), ALTO-101, and other pipeline therapies in clinical trials reflect growing R&D investment
- Improved delivery systems: Development of advanced topical vehicles, inhaled/nebulized delivery, and novel formulations is enabling broader patient populations to be treated, including milder disease cases
- Major acquisitions validating the market: Merck’s $10 billion acquisition of Verona Pharma (announced July 2025) demonstrates industry confidence in the PDE4 therapeutic class
PDE4B Inhibitor Market Players
PDE4B Inhibitor companies include:
- AbbVie
- GSK
- Pfizer
- Boehringer Ingelheim
- Chiesi
- Alto Neuroscience
- Verona Pharma
- And Others.
Download the PDE4B Inhibitor market report for in-depth insights on pipeline and forecast
PDE4B Inhibitor Epidemiology
The epidemiology section of the PDE4B inhibitor market insight report provides historical and forecasted data segmented as total cases, total eligible patient pool, and total treated cases across selected indications in the 7MM (US, EU4, UK, and Japan) from 2020 to 2034.
Key Findings:
- Based on DelveInsight’s estimates, there were approximately 30 million diagnosed prevalent cases of COPD in the 7MM in 2024, a figure expected to rise by 2034
- In 2024, the US accounted for the highest diagnosed prevalent cases of COPD, with nearly 16.5 million cases
- Among EU4 and the UK, Germany accounted for the highest share of diagnosed prevalent COPD cases in 2024 at nearly 33%, followed by France at nearly 24%, while the UK had the lowest at nearly 9%
- Japan accounted for approximately 1 million diagnosed prevalent cases of COPD in 2024
- In 2024, there were approximately 390,000 diagnosed prevalent cases of NCFB in the US, a number expected to increase by 2034
- In 2024, EU4 and the UK together accounted for approximately 620,000 diagnosed prevalent cases of NCFB, with the UK reporting the highest at nearly 230,000 cases, followed by Spain at nearly 150,000, while Germany reported the lowest at nearly 50,000 cases
- Japan accounted for nearly 9% of the total diagnosed prevalent NCFB cases in the 7MM in 2024
- In 2024, the US accounted for approximately 2 million diagnosed prevalent cases of CIAS, a number expected to rise by 2034
- Among EU4 and the UK, Germany reported the highest diagnosed prevalent CIAS cases in 2024 at nearly 458,000, while Italy had the lowest
- Japan accounted for approximately 758,000 diagnosed prevalent cases of CIAS in 2024
PDE4B Inhibitor Market Outlook
The market outlook for PDE4B inhibitors is gaining momentum as the class demonstrates strong therapeutic potential across respiratory, dermatologic, and inflammatory conditions. Approved drugs like OHTUVAYRE (ensifentrine), ZORYVE (roflumilast), and EUCRISA (crisaborole) have already validated the PDE4 pathway, while emerging candidates such as tanimilast (CHF6001) and ALTO-101 are expanding opportunities into more targeted and differentiated indications. With growing demand for safer, orally active, and more selective anti-inflammatory therapies, PDE4B inhibitors are well positioned to capture increasing market share, particularly as unmet needs in COPD, asthma, and immune-mediated diseases continue to drive innovation.
Marketed PDE4B Inhibitor Drugs
- OHTUVAYRE (ensifentrine) – Verona Pharma
OHTUVAYRE is an inhaled small-molecule therapy that acts as a dual inhibitor of PDE3 and PDE4, enzymes responsible for hydrolyzing cAMP and, in the case of PDE3, also cGMP. By blocking these pathways, ensifentrine increases intracellular cAMP and cGMP levels, leading to both bronchodilatory and anti-inflammatory effects. Delivered as an inhalation suspension, it is approved for the maintenance treatment of COPD in adults. Verona Pharma is expanding the clinical scope of ensifentrine beyond COPD, with ongoing Phase II trials evaluating its potential across NCFB, cystic fibrosis, and asthma via nebulized formulations, while MDI and DPI formulations are under evaluation for COPD, cystic fibrosis, and asthma. A nebulized combination of ensifentrine with LAMA is also being explored for maintenance treatment of COPD.
- ZORYVE (roflumilast) – Arcutis Biotherapeutics
ZORYVE is a PDE4 inhibitor that increases intracellular cAMP levels by blocking the enzyme responsible for its breakdown, modulating inflammatory pathways central to dermatologic diseases. ZORYVE cream 0.3% is approved for plaque psoriasis, including intertriginous areas, in patients 6 years and older, while the 0.15% cream is indicated for mild to moderate atopic dermatitis in the same age group. ZORYVE topical foam 0.3% is approved for seborrheic dermatitis in patients 9 years and older and for plaque psoriasis of the scalp and body in patients 12 years and older. Additionally, ZORYVE is being evaluated as a 0.05% formulation for atopic dermatitis in children aged 2–5 years and infants aged 3–24 months.
- EUCRISA (crisaborole) – Pfizer
EUCRISA is a topical PDE4 inhibitor that enhances intracellular cAMP levels, thereby modulating inflammatory responses implicated in atopic dermatitis. It is approved for the treatment of mild to moderate atopic dermatitis in adults and pediatric patients as young as 3 months, making it one of the earliest treatment options available for this condition across a wide age spectrum.
Emerging PDE4B Inhibitor Drugs
- Tanimilast (CHF6001) – Chiesi Farmaceutici
CHF6001 is an inhaled anti-inflammatory therapy under development for COPD and asthma. As a PDE4 inhibitor, it blocks the degradation of intracellular cAMP in inflammatory cells, thereby suppressing inflammation and modulating immune activity, designed to reduce airway inflammation, relieve symptoms, and improve lung function. The drug is currently in Phase III trials for COPD and Phase II trials for asthma.
- ALTO-101 – Alto Neuroscience/MEDRx
ALTO-101 is an innovative small molecule designed to treat CIAS. As a brain-penetrant PDE4 inhibitor, it targets the enzyme responsible for breaking down cAMP, a signaling molecule involved in cognition and neuroplasticity. The drug utilizes a Transdermal Delivery System (TDS) to reduce adverse events typically seen with PDE4 inhibitors, allowing for higher, more effective doses guided by EEG and behavioral biomarker readouts.
In April 2024, Alto Neuroscience reported positive Phase I results for ALTO-101, showing improved pharmacokinetics and tolerability with the transdermal delivery system compared to oral administration. In June 2024, the company initiated a Phase II trial evaluating the transdermal formulation for CIAS, with top-line results anticipated in the second half of 2025.
PDE4B Inhibitor Drugs Uptake
This section focuses on the uptake rate of potential approved and emerging PDE4B inhibitors expected to be launched in the market during 2025–2034.
Get a Comprehensive Understanding of the PDE4B Inhibitor Pipeline and Competitive Landscape
Conclusion
The PDE4B inhibitor market is positioned for sustained growth through 2034, driven by a high chronic disease burden across respiratory, dermatologic, and neuropsychiatric conditions, along with a clear physician and patient preference shift toward targeted, non-steroidal anti-inflammatory options. Approved therapies such as OHTUVAYRE (ensifentrine), ZORYVE (roflumilast), and EUCRISA (crisaborole) have already validated the clinical and commercial relevance of PDE4 modulation, while emerging candidates like tanimilast (CHF6001) and ALTO-101 are extending the class’s reach into new indications, including CIAS. Improved delivery systems and major industry moves, such as Merck’s acquisition of Verona Pharma, further reinforce confidence in this differentiated and multi-indication therapeutic class.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
